ReviewJournal of clinical medicine2026

The Evolving Role of Second- and Third-Generation Tyrosine Kinase Inhibitors in Gastrointestinal Malignancies: Advances in Targeted Therapy with Sunitinib, Regorafenib, and Avapritinib.

Piotr Kawczak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.